Hot from the Australian Society for Microbiology 2012 Annual Scientific Meeting
Clofazimine will be trialled as a new TB drug.
Prof Harvey Rubin in his plenary address on Wednesday morning 4 July discussed new findings about the action of clofazimine. This is a standard treatment for leprosy, but through its selective action of starving bacterial cells of energy, it is effective in vitro against Mycobacterium tuberculosis and some other bacteria, including Staphylococcus aureus. He says trials will commence soon to test clofazimine in people with multidrug resistant TB. This may be a major advance in battling the severe emerging global problem of drug resistant TB.
Visit the ASM 2012 Meeting website.
Mutidrug Resistance TB (World Health Organization) site: excellent resource!